Mylan Inc. April 26 announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market the first generic version of Lundbeck’s Desoxyn (methamphetamine hydrochloride tablets) based on an agreement with its licensing partner Coastal Pharmaceuticals.
Desoxyn is used for the treatment of attention deficit hyperactivity disorder or obesity, the Pittsburgh-based company said.
The drug had U.S. sales of approximately $9.3 million for the 12 months ending Dec. 31, 2009, according to IMS Health.
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.